This study seeks to investigate whether a three‐drug combination of palonosetron with dexamethasone and Fos is better than granisetron + dexamethasone + Fos in preventing CINV in patients with breast cancer receiving AC‐based regimen. The gene discussed is FOS; the disease is breast cancer.